Oncologix Tech, Inc.
Oncologix Tech, Inc. (OCLG) Revenue
Annual & quarterly revenue history · segment & region breakdown
OCLG · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsOncologix Tech, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 28.96% year-over-year from $0.00B in FY2017.
Revenue trend
2017 – 1998 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2017-08-31 | $0.00B | -$0.00B | -28.96% |
| 2016-08-31 | $0.00B | -$0.00B | -18.16% |
| 2015-08-31 | $0.00B | +$0.00B | +33.32% |
| 2014-08-31 | $0.00B | +$0.00B | +1405.45% |
| 2013-08-31 | $0.00B | +$0.00B | — |
| 2012-08-31 | $0.00B | +$0.00B | — |
| 2011-08-31 | $0.00B | +$0.00B | — |
| 2010-08-31 | $0.00B | +$0.00B | — |
| 2009-08-31 | $0.00B | +$0.00B | — |
| 2008-08-31 | $0.00B | +$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Oncologix Tech, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Oncologix Tech, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Oncologix Tech, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
OCLG revenue · 4 questionsOCLG's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 28.96% year-over-year from $0.00B in FY2017.
▸ Source: FMP · Oncologix Tech, Inc. SEC filings · GAAP · Oncologix Tech, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026